USP7 and cancer: A variety of DUB inhibitors have been verified to be effective in malignant tumors, especially those targeting USP1, USP7, and UPS14, displaying great potential for clinical application, such as ML323, SJB3-019A, KSQ-4279, Compound 4, FT671 and VLX1570 [14, 16–18, 41, 42].